Helsinn Group, Switzerland Announces Support of CancerLinQ™
LUGANO, Switzerland, November 13, 2012 /PRNewswire/ --
A Rapid Learning System in Oncology Funded by the Conquer Cancer Foundation of the American Society of Clinical Oncology
Helsinn Group announces that it has signed an agreement with the Conquer Cancer Foundation of the American Society of Clinical Oncology to provide long-term financial support for CancerLinQ™, a multi-phase initiative to build a rapid learning system in oncology. Helsinn supports the Foundation's mission to conquer cancer worldwide by funding breakthrough research and sharing cutting-edge knowledge. The Foundation's vision is a world free from the fear of cancer. The Foundation fulfills its mission by funding research and supporting the scientific and educational purposes of the American Society of Clinical Oncology (ASCO).
Helsinn is engaged in advancing knowledge, research, and quality patient care in oncology, including through the coordination and exchange of health information to optimize health outcomes, improve patients' lives, and advance patients' understanding of oncology. "Helsinn is pleased to make a long-term commitment to the Conquer Cancer Foundation of the American Society of Clinical Oncology in support of CancerLinQ™, a rapid learning system in Oncology", stated Dr. Riccardo Braglia, Helsinn's Group CEO. "Helsinn is committed to advancing quality patient care through the development and commercialization of cancer supportive care treatments to benefit both patients and caregivers," he concluded.
ASCO®, Conquer Cancer Foundation®, and CancerLinQ™ are trademarks of the American Society of Clinical Oncology. Used with permission. ASCO and Conquer Cancer Foundation are not partners or affiliates of Helsinn Group, and do not recommend or endorse any company, product, or service.
About Helsinn Group
Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United States. Helsinn's business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. Helsinn is an important player in cancer supportive care. Helsinn Group in-licenses early-to-late stage new chemical entities, completes their development through the performance of pre-clinical /clinical studies and Chemistry, Manufacturing, and Control (CMC) development, and files and attains their market approvals worldwide. Helsinn's products are out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how whom Helsinn assists and supports by providing a full range of product and scientific management services, including commercial, regulatory, financial, legal, and medical marketing advice. The active pharmaceutical ingredients and the finished products are manufactured according to the highest quality, safety, and environmental standards at Helsinn's GMP facilities in Switzerland and Ireland and supplied worldwide to its customers. Further information on Helsinn Group is available at http://www.helsinn.com .
About ASCO® and Conquer Cancer Foundation®
The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who care for people with cancer. With more than 30,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation of the American Society of Clinical Oncology, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO® information and resources, visit http://www.asco.org . Patient-oriented cancer information is available at http://www.cancer.net .
For Helsinn Group
Head of Communication & Press Office
SOURCE Helsinn Healthcare SA
Mer från detta företag
Helsinn Group and Eisai Inc. Announce Top-Line Results for Pivotal Studies of the Investigational Fixed-Dose Combination of Netupitant and Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting
16 May, 2013, 08:00 CET
Skapa innehåll för din webbplats
Förbättra din webbplats eller blogg med PR Newswires skräddarsydda nyhetsflöden.
Kontakta PR Newswire
Skicka oss ett mail till email@example.com eller ring oss på +46 (0)8 1200 1300
Bli en PR Newswire kund
Begär mer information , se PR Newswire produkter & tjänster eller ring oss på +46 (0)8 1200 1300